Last reviewed · How we verify
NCT05354960
PROMs in Lower Limb Reconstruction
trial testing Questionnaire validation in Patient Reported Outcome Measures in 150 participants. Status unknown.
31 May 2024
Quick facts
| Lead sponsor | Nicole Lindenblatt |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 June 2022 |
| Primary completion | 31 May 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Questionnaire validation
Conditions studied
- Patient Reported Outcome Measures — all drugs for Patient Reported Outcome Measures →
- Limb Injury — all drugs for Limb Injury →
- Trauma — all drugs for Trauma →
Sponsor
Nicole Lindenblatt
Who can join
18 and older, any sex, with Patient Reported Outcome Measures or Limb Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to evaluate the validity of PROMS after reconstructive surgery or amputation in the leg region. In this context, the German version of the LIMB-Q, a questionnaire-based "Patient-reported outcome measurement" (PROM), will be validated for the German-speaking region and any necessary cultural adaptations will be made for the future use of the questionnaire. In addition, the aim is to establish a context between the LIMB-Q as a PROM and clinical outcome measurements (Maryland Foot Score, American Orthopedic Foot and Ankle Society Score).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05354960
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire validation
Trials testing the same drug.
- NCT03679871 — Spiritual Assessment in Chronic Pain Patients · NA · completed
Other recruiting trials for Patient Reported Outcome Measures
Currently open trials in the same condition.
- NCT06683833 — Comparison Between Egyptian MTA, Biodentine Versus Calcium Hydroxide as Indirect Pulp Capping Materials In Permanent Tee · Phase 4 · recruiting
- NCT05989477 — At-home Breast Oncology Care Delivered With E-health Solutions · NA · recruiting
- NCT05990946 — Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assist · NA · recruiting
- NCT05307367 — Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms · NA · recruiting
- NCT05354973 — ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy · recruiting
Other Nicole Lindenblatt trials
Trials by the same sponsor.
- NCT04393168 — Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05354960 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nicole Lindenblatt
- Last refreshed: 2 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05354960.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing